Seven patients now have a name for their specific congenital disorder of glycosylation (CDG)—a new type called GALNT2-CDG. Researchers from Frontiers in Congenital Disorders of Glycosylation (FCDGC) describe the new disorder, caused by mutations in the GALNT2 gene, in the journal Brain.
Rare disease patients or their caregivers are invited to complete a 20-minute online survey from home about the ways the novel coronavirus pandemic is impacting people with rare diseases and their families.
What is the genetic cause behind impaired mucociliary clearance of the lungs? Researchers from the Genetic Disorders of Mucociliary Clearance Consortium (GDMCC) contributed to the discovery of a new disease gene, NEK10, that regulates cilia length.
For the first time, researchers have described the spectrum of mitochondrial diseases (MtDs) in North America. A new study in Neurology Genetics uses data from the North American Mitochondrial Disease Consortium (NAMDC) Registry to evaluate the clinical, biochemical, and genetic features of patients with MtDs.
The patient advocacy groups that partner with the Rare Diseases Clinical Research Network are working hard to support rare disease patients and families during the COVID-19 pandemic. Collected here are several resources they have developed to support their patient and family communities. This post will be updated as new resources are added.
A strong collaboration between researchers and patient advocacy groups in the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) is demonstrating how partnering with patients can accelerate discoveries for rare diseases.
Interested in learning more about the Rare Diseases Clinical Research Network (RDCRN)’s fourth funding cycle and hearing stories of patient engagement in research? Plan to visit the RDCRN’s poster and exhibit table at Rare Disease Day at NIH on Friday, February 28 in Bethesda, Maryland. If you’re not able to attend in person, follow the action on social media using the hashtags #RDDNIH and #RDCRNPatientPartners.